Sarah C. Adams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah C. Adams has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Mark W. Grinstaff
Boston University
3 shared publications - Aaron H. Colby
Department of Biomedical Engineering, Boston University
2 shared publications - Alexandra J. Brownstein
Metabolism Theme, David Geffen School of Medicine, University of California, Los Angeles, USA
2 shared publications - Andrew Martin
Department of Biomedical Engineering, Boston University
2 shared publications - Anton Petcherski
Department of Medicine, Endocrinology, David Geffen School of Medicine, University of California, Los Angeles, USA
2 shared publications - Brett M Tingley
Department of Biomedical Engineering, Boston University
2 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (14) , 4160-4175
A 3D microfluidic model of exchange between perfused blood and lymphatic microvascular networks
Blood and lymphatic microvascular networks function as integrated systems within tissues, exchanging fluid, molecules, and cells to regulate homeostasis and immune responses, yet current in vitro models primarily study these systems in isolation. Existing blood-lymphatic culture models either lack in vivo-like network architecture or cannot achieve independent perfusion of the two vascular compartments, preventing their use in modeling cross-network transport interactions. Here, we present a novel microfluidic platform that supports the formation of independently perfusable, self-assembled blood and lymphatic microvascular networks with physiologically relevant architecture, surface area, and spatial organization. This model was created using a tape-based laminated microfluidic device and sequential gel casting approach to spatially pattern blood and lymphatic endothelial cells within a continuous matrix environment, allowing the two networks to co-develop and become independently perfusable without compromising cross-network transport capacity. High-resolution imaging confirmed that both networks matured progressively over 5 days, maintaining distinct identities, morphology, and barrier integrity under optimized growth factor conditions. Functional validation demonstrated size-selective transport between networks and physiologically relevant T-cell migration from blood to lymphatic vessels, with enhanced trafficking under inflammatory (TNF-α), chemoattractant (SDF-1α), and activation conditions. These studies establish a new experimental platform for the investigation of molecular and cellular transport and signaling across the blood-lymphatic interface under diverse physiological and pathological conditions.
- 30 March 2026
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 26 (14) , 4160-4175
Open AccessA 3D microfluidic model of exchange between perfused blood and lymphatic microvascular networks
Blood and lymphatic microvascular networks function as integrated systems within tissues, exchanging fluid, molecules, and cells to regulate homeostasis and immune responses, yet current in vitro models primarily study these systems in isolation. Existing blood-lymphatic culture models either lack in vivo-like network architecture or cannot achieve independent perfusion of the two vascular compartments, preventing their use in modeling cross-network transport interactions. Here, we present a novel microfluidic platform that supports the formation of independently perfusable, self-assembled blood and lymphatic microvascular networks with physiologically relevant architecture, surface area, and spatial organization. This model was created using a tape-based laminated microfluidic device and sequential gel casting approach to spatially pattern blood and lymphatic endothelial cells within a continuous matrix environment, allowing the two networks to co-develop and become independently perfusable without compromising cross-network transport capacity. High-resolution imaging confirmed that both networks matured progressively over 5 days, maintaining distinct identities, morphology, and barrier integrity under optimized growth factor conditions. Functional validation demonstrated size-selective transport between networks and physiologically relevant T-cell migration from blood to lymphatic vessels, with enhanced trafficking under inflammatory (TNF-α), chemoattractant (SDF-1α), and activation conditions. These studies establish a new experimental platform for the investigation of molecular and cellular transport and signaling across the blood-lymphatic interface under diverse physiological and pathological conditions.
- Open Access
- 3 February 2025
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 8 (4) , e202403182
Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections
SARS-CoV-2 can infect cells through endocytic uptake, a process that is targeted by inhibition of lysosomal proteases. However, clinically this approach to treat viral infections has afforded mixed results, with some studies detailing an oral regimen of hydroxychloroquine accompanied by significant off-target toxicities. We rationalized that an organelle-targeted approach will avoid toxicity while increasing the concentration of the drug at the target. Here, we describe a lysosome-targeted, mefloquine-loaded poly(glycerol monostearate-co-ε-caprolactone) nanoparticle (MFQ-NP) for pulmonary delivery via inhalation. Mefloquine is a more effective inhibitor of viral endocytosis than hydroxychloroquine in cellular models of COVID-19. MFQ-NPs are less toxic than molecular mefloquine, are 100–150 nm in diameter, and possess a negative surface charge, which facilitates uptake via endocytosis allowing inhibition of lysosomal proteases. MFQ-NPs inhibit coronavirus infection in mouse MHV-A59 and human OC43 coronavirus model systems and inhibit SARS-CoV-2 WA1 and its Omicron variant in a human lung epithelium model. Organelle-targeted delivery is an effective means to inhibit viral infection.
- 3 February 2025
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 8 (4) , e202403182
Open AccessEndolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections
SARS-CoV-2 can infect cells through endocytic uptake, a process that is targeted by inhibition of lysosomal proteases. However, clinically this approach to treat viral infections has afforded mixed results, with some studies detailing an oral regimen of hydroxychloroquine accompanied by significant off-target toxicities. We rationalized that an organelle-targeted approach will avoid toxicity while increasing the concentration of the drug at the target. Here, we describe a lysosome-targeted, mefloquine-loaded poly(glycerol monostearate-co-ε-caprolactone) nanoparticle (MFQ-NP) for pulmonary delivery via inhalation. Mefloquine is a more effective inhibitor of viral endocytosis than hydroxychloroquine in cellular models of COVID-19. MFQ-NPs are less toxic than molecular mefloquine, are 100–150 nm in diameter, and possess a negative surface charge, which facilitates uptake via endocytosis allowing inhibition of lysosomal proteases. MFQ-NPs inhibit coronavirus infection in mouse MHV-A59 and human OC43 coronavirus model systems and inhibit SARS-CoV-2 WA1 and its Omicron variant in a human lung epithelium model. Organelle-targeted delivery is an effective means to inhibit viral infection.
- 8 May 2024
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 210, 115331
Immunotherapies for locally aggressive cancers
- 8 May 2024
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 210, 115331
Immunotherapies for locally aggressive cancers
- Open Access
Endo-Lysosome-Targeted Nanoparticle Delivery of Antiviral Therapy for Coronavirus Infections
SARS-CoV-2 can infect cells through endocytic uptake, a process which is targeted by inhibition of lysosomal proteases. However, clinically this approach to treat viral infections has afforded mixed results, with some studies detailing an oral regimen of hydroxychloroquine accompanied by significant off-target toxicities. We rationalized that an organelle-targeted approach will avoid toxicity while increasing the concentration of the drug at the target. Here we describe a lysosome-targeted, mefloquine-loaded poly(glycerol monostearate-co-ε-caprolactone) nanoparticle (MFQ-NP) for pulmonary delivery via inhalation. Mefloquine is a more effective inhibitor of viral endocytosis than hydroxychloroquine in cellular models of COVID-19. MFQ-NPs are less toxic than molecular mefloquine, 100-150 nm in diameter, and possess a negative surface charge which facilitates uptake via endocytosis allowing inhibition of lysosomal proteases. MFQ-NPs inhibit coronavirus infection in mouse MHV-A59 and human OC43 coronavirus model systems and inhibit SARS-CoV-2-WA1 and its Omicron variant in a human lung epithelium model. This study demonstrates that organelle-targeted delivery is an effective means to inhibit viral infection.
Open AccessEndo-Lysosome-Targeted Nanoparticle Delivery of Antiviral Therapy for Coronavirus Infections
SARS-CoV-2 can infect cells through endocytic uptake, a process which is targeted by inhibition of lysosomal proteases. However, clinically this approach to treat viral infections has afforded mixed results, with some studies detailing an oral regimen of hydroxychloroquine accompanied by significant off-target toxicities. We rationalized that an organelle-targeted approach will avoid toxicity while increasing the concentration of the drug at the target. Here we describe a lysosome-targeted, mefloquine-loaded poly(glycerol monostearate-co-ε-caprolactone) nanoparticle (MFQ-NP) for pulmonary delivery via inhalation. Mefloquine is a more effective inhibitor of viral endocytosis than hydroxychloroquine in cellular models of COVID-19. MFQ-NPs are less toxic than molecular mefloquine, 100-150 nm in diameter, and possess a negative surface charge which facilitates uptake via endocytosis allowing inhibition of lysosomal proteases. MFQ-NPs inhibit coronavirus infection in mouse MHV-A59 and human OC43 coronavirus model systems and inhibit SARS-CoV-2-WA1 and its Omicron variant in a human lung epithelium model. This study demonstrates that organelle-targeted delivery is an effective means to inhibit viral infection.